2023 Approvals

FDA Approves SKYCLARYS to Aid Friedreich’s Ataxia Patients on February 28, 2023

FDA Approves SKYCLARYS to Aid Friedreich’s Ataxia Patients on February 28, 2023

What is SKYCLARYS  prescribed for?  SKYCLARYS is prescribed for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. What is the name of the drug and what does it do?  SKYCLARYS is a medication for adults and teenagers aged 16 years and above who have Friedreich’s ataxia (FA).  FA is a rare genetic...

FDA Approves FILSPARI to Aid Kidney Health in IgA Nephropathy on February 2023

FDA Approves FILSPARI to Aid Kidney Health in IgA Nephropathy on February 2023

What is FILSPARI prescribed for?   FILSPARI is prescribed to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression. What is the name of the drug and what does it do?  FILSPARI (generic name: sparsentan), pronounced “fil spah’ ree,” is a medicine that helps adults with a kidney condition called...

EXXUA: A Groundbreaking Step for Treating Major Depression Approved on September 22, 2023

EXXUA: A Groundbreaking Step for Treating Major Depression Approved on September 22, 2023

What is EXXUA prescribed for?   EXXUA is  prescribed to treat major depressive disorder in adults.  What is the name of the drug and what does it do? EXXUA, pronounced EKS-shoo-uh, (generic name: gepirone)  is a new medication approved by the FDA for treating adults with major depressive disorder (MDD).  This drug offers a new option...

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

OJJAARA: A New Treatment for Myelofibrosis Approved by the FDA on September 15, 2023

What is OJJAARA prescribed for?  OJJAARA is prescribed to treat intermediate or high-risk myelofibrosis in adults with anemia.  What is the name of the drug and what does it do? OJJAARA, pronounced oh-JAR-uh, (generic name: momelotinib) is a medication approved on September 15, 2023, for the treatment of adults with intermediate or high-risk myelofibrosis,...

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

APHEXDA: A New Frontier in Multiple Myeloma Treatment Approved by the FDA on September 8, 2023

What is APHEXDA prescribed for?  APHEXDA is used in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. What is the name of the drug and what does it do? APHEXDA , pronounced ah fex’ dah, (generic name: motixafortide) is a...